FREE LIVE REAL WORLD MASTERCLASS SERIES 2022-2023
‘How to ensure success and avoid pitfalls in Real World studies by Understanding Healthcare in Europe and Asia’
Dates: Monthly starting in February 2022 | Time: 5pm CET | 4pm UK | 11am EST | 8am PST
OXON is resuming the series of masterclasses on real world evidence starting in February 2022
This Masterclass series follows the successful Masterclasses in 2021on real-world studies and RCTs by OXON and the eminent statistician, Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine (devised: ‘Pocock Stopping Rule’, ‘Win Ratio’. ‘Individualising benefit-risk’); extensive experience with EMA/FDA and data monitoring committees (including adaptive platform Covid-19 DISCOVERY trial); >500 publications (100+ NEJM/Lancets) mainly of trials and epidemiology.
The series provides practical knowledge and advice from national academic experts to apply to field, secondary data and hybrid observational studies for safety, HEOR/market access and clinical development. It is aimed at professionals in the biopharmaceutical and medical device industries, anywhere in the world, involved in the production of real-world evidence and conduct of observational studies in Europe and Asia.
UPCOMING MASTERCLASSES CALENDAR
About OXON’s Free Live Masterclass Series on RW Studies
These are masterclass sessions to understand the healthcare for RW studies, led by leading professors of pharmacoepidemiology in Europe and Asia, centred on the practical theme of “How to ensure success of your RWE studies and avoid pitfalls”
The series will be delivered by leading native pharmacoepidemiologists together with OXON, and it will be centred on understanding healthcare and data sources to fulfil RW field and secondary data studies in their various countries.
The current series will highlight the changes and data sources as a result of the Covid-19 pandemic.
The series will have additional ad-hoc Masterclasses on specific topics, such as:
- External Control Groups for Regulatory and HTA submissions
- Hybrid Pregnancy Safety Studies: New Approach
- Multi-country RW Data Collection Studies
- Multi-country RW Secondary Data Studies
- Evaluation of Risk Minimization Measures (with an ex-PRAC member)
We will involve Professor Stuart Pocock’s extensive experience of trials, epidemiology, data monitoring and EMA/FDA for several of these topics.